View in EDS HTML Full Text PDF Full Text

Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.

Saved in:
Bibliographic Details
Title: Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
Authors: Bourdin, Arnaud (AUTHOR), Shaw, Dominick (AUTHOR), Menzies-Gow, Andrew (AUTHOR), FitzGerald, J. Mark (AUTHOR), Bleecker, Eugene R. (AUTHOR), Busse, William W. (AUTHOR), Ferguson, Gary T. (AUTHOR), Brooks, Laura (AUTHOR), Barker, Peter (AUTHOR), Gil, Esther Garcia (AUTHOR), Martin, Ubaldo J. (AUTHOR)
Source: Journal of Asthma. Apr2021, Vol. 58 Issue 4, p514-522. 9p.
Subjects: Drug efficacy, Asthma, Corticosteroids
Abstract: Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year and decreases oral corticosteroid (OCS) use after 28 weeks for patients with severe, uncontrolled eosinophilic asthma. We assessed whether these effects on OCS reduction are sustained for up to an additional year of treatment while maintaining an acceptable safety profile. Data on OCS maintenance dosage were collected for adult patients with baseline blood eosinophil counts ≥150 cells/μL treated with add-on benralizumab 30 mg (every 4 [Q4W] or 8 weeks [Q8W; first three doses Q4W]) from the 28-week ZONDA study and were integrated with results from the predefined 56-week adult completion phase of the BORA extension study. Efficacy and safety were summarized descriptively. For patients receiving benralizumab Q8W, the median daily OCS dosage reduction of 75% from baseline to end of treatment achieved in ZONDA was sustained at the end of the BORA extension period (median 67% reduction from baseline). This was estimated to result in a median cumulative OCS dosage of 2.98 g over the 1.5-year period for patients receiving benralizumab Q8W compared with 5.74 g if these patients had remained on their baseline OCS dosages prior to benralizumab initiation. All adverse event rates were similar between the BORA extension and ZONDA periods, with no new or unexpected safety findings. This benralizumab 1.5-year integrated analysis demonstrates that OCS reductions and safety were maintained with further follow up and supports long-term use of benralizumab for patients with severe, uncontrolled eosinophilic asthma. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Asthma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 149525586
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Bourdin%2C+Arnaud%22">Bourdin, Arnaud</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Shaw%2C+Dominick%22">Shaw, Dominick</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Menzies-Gow%2C+Andrew%22">Menzies-Gow, Andrew</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22FitzGerald%2C+J%2E+Mark%22">FitzGerald, J. Mark</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bleecker%2C+Eugene+R%2E%22">Bleecker, Eugene R.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Busse%2C+William+W%2E%22">Busse, William W.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ferguson%2C+Gary+T%2E%22">Ferguson, Gary T.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Brooks%2C+Laura%22">Brooks, Laura</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Barker%2C+Peter%22">Barker, Peter</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gil%2C+Esther+Garcia%22">Gil, Esther Garcia</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Martin%2C+Ubaldo+J%2E%22">Martin, Ubaldo J.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+Asthma%22">Journal of Asthma</searchLink>. Apr2021, Vol. 58 Issue 4, p514-522. 9p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+efficacy%22">Drug efficacy</searchLink><br /><searchLink fieldCode="DE" term="%22Asthma%22">Asthma</searchLink><br /><searchLink fieldCode="DE" term="%22Corticosteroids%22">Corticosteroids</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year and decreases oral corticosteroid (OCS) use after 28 weeks for patients with severe, uncontrolled eosinophilic asthma. We assessed whether these effects on OCS reduction are sustained for up to an additional year of treatment while maintaining an acceptable safety profile. Data on OCS maintenance dosage were collected for adult patients with baseline blood eosinophil counts ≥150 cells/μL treated with add-on benralizumab 30 mg (every 4 [Q4W] or 8 weeks [Q8W; first three doses Q4W]) from the 28-week ZONDA study and were integrated with results from the predefined 56-week adult completion phase of the BORA extension study. Efficacy and safety were summarized descriptively. For patients receiving benralizumab Q8W, the median daily OCS dosage reduction of 75% from baseline to end of treatment achieved in ZONDA was sustained at the end of the BORA extension period (median 67% reduction from baseline). This was estimated to result in a median cumulative OCS dosage of 2.98 g over the 1.5-year period for patients receiving benralizumab Q8W compared with 5.74 g if these patients had remained on their baseline OCS dosages prior to benralizumab initiation. All adverse event rates were similar between the BORA extension and ZONDA periods, with no new or unexpected safety findings. This benralizumab 1.5-year integrated analysis demonstrates that OCS reductions and safety were maintained with further follow up and supports long-term use of benralizumab for patients with severe, uncontrolled eosinophilic asthma. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Journal of Asthma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=149525586
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/02770903.2019.1705333
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 9
        StartPage: 514
    Subjects:
      – SubjectFull: Drug efficacy
        Type: general
      – SubjectFull: Asthma
        Type: general
      – SubjectFull: Corticosteroids
        Type: general
    Titles:
      – TitleFull: Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bourdin, Arnaud
      – PersonEntity:
          Name:
            NameFull: Shaw, Dominick
      – PersonEntity:
          Name:
            NameFull: Menzies-Gow, Andrew
      – PersonEntity:
          Name:
            NameFull: FitzGerald, J. Mark
      – PersonEntity:
          Name:
            NameFull: Bleecker, Eugene R.
      – PersonEntity:
          Name:
            NameFull: Busse, William W.
      – PersonEntity:
          Name:
            NameFull: Ferguson, Gary T.
      – PersonEntity:
          Name:
            NameFull: Brooks, Laura
      – PersonEntity:
          Name:
            NameFull: Barker, Peter
      – PersonEntity:
          Name:
            NameFull: Gil, Esther Garcia
      – PersonEntity:
          Name:
            NameFull: Martin, Ubaldo J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: Apr2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 02770903
          Numbering:
            – Type: volume
              Value: 58
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Journal of Asthma
              Type: main
ResultId 1